Investors focused on the Medical space have likely heard of Gilead Sciences (GILD), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Gilead Sciences is a member of our Medical group, which includes 844 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. GILD is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for GILD's full-year earnings has moved 5.91% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that GILD has returned about 6.94% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 4.09% on a year-to-date basis. As we can see, Gilead Sciences is performing better than its sector in the calendar year.
Looking more specifically, GILD belongs to the Medical - Biomedical and Genetics industry, which includes 352 individual stocks and currently sits at #79 in the Zacks Industry Rank. On average, this group has gained an average of 2.47% so far this year, meaning that GILD is performing better in terms of year-to-date returns.
GILD will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research